Antigen-specific T-lymphocyte function after cord blood transplantation.
It has not been possible to determine the singular contribution of naive T lymphocytes to antigen-specific immunity after hematopoietic stem cell transplantation (HSCT), because of the confounding effects of donor-derived antigen-specific T lymphocytes present in most hematopoietic stem cell (HSC) products. Because umbilical cord blood contains only naive T lymphocytes, we longitudinally evaluated the recipients of unrelated cord blood transplantation (UCBT) for the presence of T lymphocytes with specificity for herpesviruses, to determine the contribution of the naive T lymphocytes to antigen-specific immune reconstitution after HSCT. Antigen-specific T lymphocytes were detected early after UCBT (herpes simplex virus on day 29; cytomegalovirus on day 44; varicella zoster virus on day 94). Overall, 66 of 153 UCBT recipients developed antigen-specific T lymphocytes to 1 or more herpesviruses during the evaluation period. The likelihood of developing antigen-specific T lymphocyte function was not associated with immunophenotypic T lymphocyte reconstitution, transplant cell dose, primary disease, or acute and chronic graft-versus-host disease. These results indicate that naive T lymphocytes present in the HSC inoculum can contribute to the generation of antigen-specific T-lymphocyte immunity early after transplantation.
Cohen
Geoff
G
The EMMES Corporation, Rockville, Maryland, USA.
Carter
Shelly L
SL
Weinberg
Kenneth I
KI
Masinsin
Bernadette
B
Guinan
Eva
E
Kurtzberg
Joanne
J
Wagner
John E
JE
Kernan
Nancy A
NA
Parkman
Robertson
R
D000293:Adolescent; D000914:Antibodies, Viral / Q000097:blood; D019070:Cell Lineage; D002648:Child; D002675:Child, Preschool; D017322:Clinical Trials, Phase II as Topic / Q000706:statistics & numerical data; D036101:Cord Blood Stem Cell Transplantation; D003587:Cytomegalovirus / Q000276:immunology / Q000502:physiology; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D005188:False Negative Reactions; D005260:Female; D005312:Fetal Blood / Q000276:immunology; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000209:etiology / Q000276:immunology; D006561:Herpes Simplex / Q000175:diagnosis / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D006562:Herpes Zoster / Q000175:diagnosis / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D014645:Herpesvirus 3, Human / Q000276:immunology / Q000502:physiology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007239:Infections / Q000276:immunology / Q000401:mortality; D008297:Male; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data; D011183:Postoperative Complications / Q000276:immunology / Q000401:mortality; D011184:Postoperative Period; D018139:Simplexvirus / Q000276:immunology / Q000502:physiology; D037182:T-Cell Antigen Receptor Specificity; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D013997:Time Factors; D016896:Treatment Outcome; D014775:Virus Activation
D000914:Antibodies, Viral